Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Adenosine Monophosphate Clear all

Conditions: Ankle Fractures
Interventions: Ankle Muscle Power (AMP) program, Standard of Care; Other · Behavioral
Lead sponsor: Brian W. Noehren; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis, Hypertriglyceridemia Acute Pancreatitis, Idiopathic (Unknown) Acute Pancreatitis, Medication Induced Acute Pancreatitis, Cancer Acute Pancreatitis, Miscellaneous (i.e. Acute on Chronic Pancreatitis)
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Solid Tumor
Interventions: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Hepatitis C, Chronic
Interventions: Liver Biopsy, Peginterferon & Ribavirin for Hepatitis C, Pre-treatment Ribavirin; Procedure · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lupus Nephritis
Interventions: Pentoxifylline, Placebos; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: End-Stage Renal Disease
Interventions: ESA Dose Adjustment per standard Anemia Management Protocol, ESA Dose Adjustment per "Smart Anemia Manager" Algorithm; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pregnancy, IUGR, Preeclampsia
Interventions: Collection of myometrial, cord blood, and placental tissue samples; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Advanced Unresectable Hepatocellular Carcinoma
Interventions: RBS2418, STRIDE (durvalumab + tremelimumab); Drug
Lead sponsor: Riboscience, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Nashville, Tennessee • Dallas, Texas + 1 more

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 65 Years
Enrollment: 72 participants
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Adenylosuccinate Synthase 1 Deficient Myopathy
Interventions: adenylosuccinic acid; Drug
Lead sponsor: Cure ADSSL1; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Generalized Anxiety Disorder
Interventions: AMP, Applied Relaxation (AR), Clinical Monitoring (CM), Combining the AMP and AR; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Olfactory Disorder
Interventions: saline nasal irrigation; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: tocladesine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 1999
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Aging, Insulin Sensitivity, Chronic Disease, Mitochondria, Insulin Resistance
Interventions: Metformin, Placebo oral tablet; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 40 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Madison, Wisconsin

Conditions: Obsessive Compulsive Disorder
Interventions: Attention Modification Program; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 8 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: In-home asthma management program (AMP) provided by nurses, In-home asthma management program (AMP) provided by respiratory therapists; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 64 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Receptor Blockade
Interventions: Adenosine Triphosphate, Acetylcholine, Sodium Nitroprusside, Adenosine Diphosphate, Adenosine Monophosphate, Uridine Triphosphate, Adenosine, Vitamin B 6, Pyridoxal 5'-Phosphate; Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Colorectal Cancer
Interventions: tocladesine; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ischemia
Interventions: Adenosine, Adenosine Mono Phosphate (AMP); Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions: RBS2418, Placebo; Drug
Lead sponsor: Riboscience, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Newark, Delaware • Las Vegas, Nevada • Nashville, Tennessee + 1 more

Conditions: Recurrent Aphthous Stomatitis
Interventions: Apremilast 30mg; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Sinusitis
Interventions: Not listed
Lead sponsor: Greg Davis; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: ADHD, Autism Spectrum Disorder
Interventions: Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.; Drug
Lead sponsor: Daniel Coury; Other
Eligibility: 4 Years to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Irvine, California • Los Angeles, California • Portland, Maine + 8 more

Conditions: HIV Infections
Interventions: Amp; Behavioral
Lead sponsor: Sentient Research; Industry
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: West Covina, California

Search by objective public record fields.

Efficacy and Clinical Feasibility of the Ankle Muscle Power (AMP) Program for Return to Duty After an Ankle Fracture

Pentoxifylline Treatment in Acute Pancreatitis (AP)

Study of SRF617 in Patients With Advanced Solid Tumors

Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C

Pentoxifylline in Lupus Nephritis

Intelligent Control Approach to Anemia Management

Effects of High Altitude on AMPK Activation

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3)

A Phase 1b Study of Adenylosuccinic Acid (ASA-001) for Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy.

Attention Training for Generalized Anxiety Disorder

cAMP (Cyclic Adenosine Monophosphate) Levels in the Nose

Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma

Antecedent Metabolic Health and Metformin Aging Study

Attention Training for Childhood Obsessive Compulsive Disorder: An Open Case Series

This Study Compared an in Home Asthma Management Program Provided by Nurses or Respiratory Therapist

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer

AMP as a Better Delivery System of Adenosine

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Apremilast for RAS

Olfactory Dysfunction of Rhinosinusitis - Cyclic Adenosine Monophosphate (cAMP)/Calcium Signaling Study

AWARE: Management of ADHD in Autism Spectrum Disorder

Quantitative and Qualitative Research for "mHealth Program to Support People Living With HIV Across the HIV Care Continuum"